Forex losses seen denting Ranbaxy's Q3 performance
This article was originally published in Scrip
Executive Summary
Forex losses, mainly of the mark-to-market (MTM) type, are expected to impair Ranbaxy's performance for the third quarter ended 30 September, even as speculation continues unabated on the firm's plans to launch a generic version of Pfizer's Lipitor (atorvastatin) in the US at the end of the month.